H.C. Wainwright analyst Swayampakula Ramakanth has maintained their bullish stance on OCGN stock, giving a Buy rating on March 4.
Swayampakula Ramakanth’s rating is based on Ocugen’s strategic plans to submit three Biologics License Applications (BLAs) over the next three years, which could significantly enhance their revenue streams. The company aims to commercialize its gene therapy products, OCU400, OCU410ST, and OCU410, with expected submissions in 2026, 2027, and 2028, respectively. This timeline is supported by Ocugen’s progress in clinical trials, including the ongoing Phase 3 study for OCU400, which is on track to meet its enrollment goals.
Furthermore, the recent classification of OCU400 as an Advanced Therapy Medicinal Product by the European Medicines Agency suggests regulatory confidence, potentially speeding up the review process. Ocugen’s financial position, with $58.8 million in cash and cash equivalents, is deemed sufficient to support operations until the first quarter of 2026. These factors, combined with anticipated data updates from ongoing studies, underpin Ramakanth’s optimistic outlook and Buy rating for Ocugen’s stock.
In another report released on March 4, Noble Financial also reiterated a Buy rating on the stock with a $8.00 price target.